Vios Fertility Institute Patients Are First to Have Embryos Transferred to TMRW

As Egg Freezing and IVF Rates Hit New Highs, Vios Fertility Institute Goes LIVE with TMRW, the World’s First Technology Platform that Stores, Manages, and Identifies Frozen Eggs and Embryos

Chicago Couple is First to Have Embryos Transferred

 

CHICAGO, IL (February 3, 2021) – By the year 2100, approximately 300 million people will be born from in vitro fertilization (IVF), something that seemed impossible until the birth of Louise Brown in 1978. TMRW Life Sciences (“TMRW”) is determined to assist in those future births by effectively managing all frozen fertility specimens with the first and only automated technology platform that safely stores, manages and identifies frozen eggs and embryos. Today, Vios Fertility Institute – Chicago announces it is the first clinic to go live and begin storing patient specimens.

TMRW technology platform at Vios“No one undertaking IVF should ever have to worry about the safety of their embryos and eggs,” said Joshua Abram, Founder and Co-CEO of TMRW. “Three hundred million babies are expected to be born via IVF globally by 2100. With TMRW we have brought the safe storage and management of life’s most precious cells into the 21st Century.”

TMRW is the solution to a wide range of issues that have plagued fertility clinics through the years such as embryo mix-ups, incorrect transfers of embryos and catastrophic failures that resulted in the loss of thousands of irreplaceable eggs and embryos. While current methods are manual and labor intensive, they have remained unchanged since the advent of IVF. TMRW’s technology automates and digitizes the entire process, which helps reduce the risk for human error and more importantly, allows the clinic to individually track eggs and embryos 24/7 through remote monitoring, sensors and state of the art software.

Additionally, TMRW’s automated solution improves IVF by replacing the current archaic system of storage — which is not equipped to handle the soon to be hundreds of millions of fertility specimens — with a cryo-robot featuring secure, reliable technology that dramatically reduces risk and provides peace of mind.

“As we see a substantial increase in patients seeking IVF and in egg freezing – up 41% percent and 31.5% over the previous year – I am thrilled that Vios is the first fertility clinic in the world that offers TMRW to its patients,” explains Dr. Angie Beltsos, CEO & Chief Medical Officer of Vios Fertility Clinic. “IVF patients and those wanting to preserve their fertility deserve the most sophisticated care available, and there is nothing more powerful than combining our top-notch embryology services with TMRW’s game-changing technology. The peace of mind the TMRW platform offers extends to doctors, embryologists and patients alike.”

Chicago couple, Mayrav Dolgin and Renee Genova, have received fertility treatments at Vios Fertility Clinic resulting in two beautiful sons -Jonah age 2 and Elan 6 mos. They are the first patients of Vios to have their remaining embryos stored using TMRW’s new platform.

“The fertility journey can be difficult enough without having to worry about the safety of your embryos,” explains Dolgin. “Mayrav and I were ecstatic to learn that our precious embryos would be the first to be stored in the TMRW cryo-robot,” adds Genova. “Knowing that our remaining embryos will be cared for and looked after with the most advanced technology available gives us tremendous reassurance that our ability to continue building our family in the future is protected.”

The TMRW platform’s key proprietary features include:

  • A 24/7 state-of-the-art, cloud-based monitoring system that makes thousands of wellness checks on stored samples every day. TMRW’s onsite and remote communication system uses predictive analytics to proactively identify and address any safety or storage trends before they become issues.
  • Each patient is assigned an RFID tag with a unique identifier, enabling clinics to identify and track every fertility cell, dramatically reducing the possibility of mislabeled or missing samples.
  • An encrypted, HIPAA-compliant software system, providing the highest level of data privacy and security available.
  • Proprietary labware with thermal properties and proven storage freezer provides the ability to maintain safe cryogenic temperatures to safeguard eggs and embryos even without electrical power or human intervention for more than two weeks, in case of severe emergencies such as natural disasters.

Towards the end of the year, TMRW plans to launch an app that will allow patients to track their frozen specimens using a smartphone. By the end of 2021, TMRW’s platform will be used in leading fertility clinics comprising more than 30% of all IVF cycles in the U.S. The company hopes to expand into UK-based fertility clinics in summer of 2021.

About Vios Fertility:
Established in 2015, Vios Fertility Institute is one of the fastest growing fertility clinics in the U.S. with 11 locations in the Chicago, Milwaukee and St. Louis regions. Woman owned, the Vios mission is to help patients find their way to fertility health with the highest chances of success. Vios offers innovative, scientific, and cutting-edge treatment options along with an unparalleled patient experience. www.ViosFertility.com

About TMRW Life Sciences:
TMRW has created the world’s first automated platform designed specifically for cryo-management of eggs and embryos used in IVF. TMRW’s RFID-enabled, complete digital chain of custody SaaS technology radically improves on the error-prone manual and analog methods that have gone unchanged throughout the history of IVF, significantly reducing the chances of implantation mix-ups or loss of eggs and embryos. The TMRW team includes many of the world’s most celebrated innovators in fertility, embryology, cryo-management, automation, software development and robotics to name a few of the disciplines involved. TMRW’s co-founders, Joshua Abram, Alan Murray, and Dr. Jeffrey Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion. To date, TMRW has raised $50 million. For more information, please visit TMRW.org.